Immunome Inc.

NASDAQ: IMNM · Real-Time Price · USD
10.23
0.29 (2.92%)
At close: Aug 15, 2025, 3:46 PM

Immunome Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-292.96M -106.81M -36.9M -24.71M
Depreciation & Amortization
2.1M 728K 631K 755K
Stock-Based Compensation
15.75M 6.22M 5.33M 3.45M
Other Working Capital
5.35M 12.61M 2.92M 998K
Other Non-Cash Items
149.44M 80.29M 7.27M 4K
Deferred Income Tax
n/a n/a -7.27M -500K
Change in Working Capital
14.87M 12M 2.24M 2.78M
Operating Cash Flow
-110.79M -7.57M -28.69M -18.23M
Capital Expenditures
-7.17M -831K -248K -79K
Cash Acquisitions
n/a 9.28M n/a n/a
Purchase of Investments
-186.56M -38.93M n/a n/a
Sales Maturities Of Investments
155M n/a n/a n/a
Other Investing Acitivies
-46.34M n/a n/a n/a
Investing Cash Flow
-85.06M -30.48M -248K -79K
Debt Repayment
n/a n/a n/a -113K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a 116.37M n/a 656K
Financial Cash Flow
240.53M 116.41M 32K 27.77M
Net Cash Flow
44.67M 78.36M -28.91M 9.46M
Free Cash Flow
-117.97M -8.4M -28.94M -18.3M